Implant dentistry to enter new era with launch of Xeal™ and TiUltra™ surfaces from Nobel Biocare
March 12, 2019
Nobel Biocare is inviting dental professionals to join the Mucointegration™ era with the launch of the Xeal and TiUltra surfaces at the International Dental Show (IDS) in Cologne. Applied to not only implants but also abutments, these new surfaces were created to optimize tissue integration at every level for the purpose of improved implant treatment outcomes.
Based on its decades-long expertise in applied anodization technology, Nobel Biocare has understood that for optimal integration of dental implant restorations, different tissues demand different surfaces. While osseointegration is fundamental for the long-term function of implant restorations, soft-tissue integration is often overlooked. Dense soft-tissue contact with the abutment, however, can act as a barrier to protect the underlying bone 1,2,3,4.
To maintain long-term tissue health and stability, surface chemistry as well as topography of the new Xeal abutment was specially designed to facilitate soft-tissue attachment to the abutment. Backed by data from a clinical study with two-years’ follow-up, the Xeal surface has demonstrated a significant increase in soft-tissue height compared to machined abutment surfaces 5. Made available for the On1 Base and Multi-unit Abutment from Nobel Biocare, dental professionals will now be able to see and experience this pioneering MucointegrationTM surface at the IDS in Cologne.
Developed with the ultimate goal of early osseointegration and long-term bone stability in mind, the ultra-hydrophilic, multi-zone implant surface, TiUltra, is taking anodization technology a step further. Going beyond just roughness, the surface chemistry was optimized with the goal to positively influence its interaction with cells and ultimately osseointegration. TiUltra’s topography has also been reimagined to gradually change from a minimally rough and non-porous collar to a moderately rough and porous implant apex thus respecting the natural transition from hard, dense cortical bone to cancellous bone 6.
The TiUltra surface will be available with Nobel Biocare’s NobelActive and NobelParallel Conical Connection implants. Combined with the Xeal abutment surface, dental professionals have a new complete solution for soft-tissue health, bone protection and early osseointegration at their disposal. To ensure that every implant and abutment is delivered in pristine condition, the surface chemistry and hydrophilicity of both Xeal and TiUltra is preserved with a protective layer that dissolves upon contact with fluids.
“Having mastered osseointegration for decades, Nobel Biocare is taking tissue integration to a new level. With the launch of Xeal and TiUltra at IDS Cologne we are not only advancing our leadership position in surface technology but also opening a new era for implant dentistry, that of MucointegrationTM,” Hans Geiselhöringer, President of Nobel Biocare, commented at launch. “Our focus has always been on the patient. These new solutions are supported by clinical evidence including a two-year clinical trial.”
Dental professionals in CE markets will be the first to get access to the new surfaces in April, followed by other regions around the globe.* A unique insight into the scientific evidence already available on the new surfaces will be published in a dedicated supplement of the journal Clinical Implant Dentistry and Related Research with seven studies expected to be released online in March.
Visitors to IDS Cologne who want to find out more about the innovative features of Xeal and TiUltra and how they can benefit their patients, are invited to visit booth H020-J029 in hall 10.1. Nobel Biocare also provides information online at nobelbiocare.com/surface.
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.